Document is current
Any future updates will be listed below
-
Authors
Pytell, Jarratt D.
Christine, Paul J.
LeMasters, Katherine
Rockhill, Karilynn M.
Black, Joshua C.
Dart, Richard C.
Binswanger, Ingrid A.
-
Funding
Funding for this research was provided by:
Pharmaceutical Research and Manufacturers of America Foundation
National Institute on Drug Abuse (K23DA060358)
The Lifespan/Brown Criminal Justice Research Training Program on Substance Use and HIV
- License Information
-
More Information
Article History
Received: 2 August 2024
Accepted: 24 January 2025
First Online: 11 February 2025
Declarations
:
: Jarratt Pytell received a Faculty Start Grant from the PhRMA Foundation supporting this work. The funders had no role in the acquisition of data, study design, analysis, interpretation of results, or dissemination of the work. Dr. Ingrid Binswanger reports royalties from UpToDate. Drs. Rockhill, Black, and Dart are employees of Rocky Mountain Poison & Drug Safety (RMPDS), a division of nonprofit Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. DHHA/RMPDS operates the NMURx program. Outside of this work, RMPDS is supported by subscriptions from pharmaceutical manufacturers, government, and non-government agencies for surveillance, research and reporting services. No subscriber participated in the conception, analysis, drafting, or review of this manuscript.
